The Science of GNAS Mutations: Why Fibrous Dysplasia Lesions Produce Excess FGF23

Fibrous dysplasia (FD) is a rare bone disorder in which normal bone is replaced by fibrous tissue, leading to deformities, fractures and pain. When FD occurs as part of McCune-Albright syndrome (MAS), patients often develop osteomalacia associated with McCune-Albright syndrome, a condition marked by soft, weak bones due to low phosphate levels. Central to this process are mutations in the GNAS gene and the overproduction of fibroblast growth factor 23 (FGF23). Understanding these mechanisms can help guide better diagnosis and treatment.

GNAS Mutations: The Molecular Trigger

• The GNAS gene encodes the alpha subunit of the G protein (Gsα), which activates cyclic AMP (cAMP) signaling in many tissues.
• In FD/MAS, a somatic (post-zygotic) mutation in GNAS results in a Gsα protein that is stuck “on,” constantly stimulating cAMP production.
• Excess cAMP alters normal bone cell (osteoblast) function, causing them to produce fibrous tissue instead of mature bone.

Key facts about GNAS mutations in FD/MAS:

• They occur early in embryonic development, leading to mosaic patterns of disease in bone, skin and endocrine organs.
• The severity of FD and associated endocrine problems depends on how many cells carry the mutation and where they reside.
• GNAS mutations themselves do not directly cause phosphate wasting, but they set off a cascade that leads to elevated FGF23.

FGF23: The Link Between Bone Lesions and Phosphate Loss

Fibroblast growth factor 23 (FGF23) is a hormone produced primarily by osteocytes and osteoblasts in bone. Its main role is to regulate phosphate and vitamin D metabolism:

• Phosphate handling: FGF23 reduces phosphate reabsorption in the kidneys by downregulating sodium-phosphate co-transporters.
• Vitamin D regulation: FGF23 decreases the enzyme 1α-hydroxylase, lowering active vitamin D (calcitriol) levels.

In FD lesions:

• Mutant bone cells overexpress FGF23 due to aberrant cAMP signaling.
• Circulating FGF23 levels can rise dramatically, even if only a small portion of the skeleton is affected.
• High FGF23 drives phosphate into the urine (phosphaturia) and reduces intestinal phosphate absorption (via calcitriol reduction).

How Excess FGF23 Leads to Osteomalacia Associated with McCune-Albright Syndrome

Osteomalacia refers to defective bone mineralization in adults, resulting in soft bones prone to bending and fractures. In MAS patients with FD:

1. Phosphate depletion

   • Persistent FGF23 elevation causes chronic phosphate wasting.
   • Blood phosphate levels drop (hypophosphatemia), depriving bone of a critical building block.

2. Low active vitamin D

   • FGF23 decreases calcitriol synthesis, further reducing intestinal absorption of calcium and phosphate.

3. Impaired mineralization

   • Osteoblasts cannot lay down sufficient hydroxyapatite (calcium-phosphate crystals) in the bone matrix.
   • Bones become soft, leading to symptoms of osteomalacia: diffuse bone pain, muscle weakness, waddling gait and higher fracture risk.

Key points:

• Osteomalacia in MAS can be subtle at first, with mild bone pain and fatigue.
• Over time, phosphate loss and low calcitriol create a cycle of worsening bone health.
• Early recognition and treatment of phosphate and vitamin D deficiencies can slow progression.

Clinical Presentation and Diagnosis

People with FD/MAS and osteomalacia often present in childhood or early adulthood with a mix of skeletal and endocrine signs:

Skeletal features:

• Bone pain and tenderness, especially in weight-bearing bones.
• Fractures with minimal trauma.
• Bowing of long bones (e.g., femur), leading to limp or waddling gait.

Endocrine features (MAS):

• Café-au-lait skin spots (irregular, coast-of-Maine borders).
• Precocious (early) puberty in girls, testicular abnormalities in boys.
• Hyperthyroidism, growth hormone excess, Cushing’s syndrome in some cases.

Laboratory findings:

• Low serum phosphate.
• High urinary phosphate excretion.
• Elevated FGF23 levels (measured in specialized labs).
• Low or inappropriately normal calcitriol.

Imaging studies:

• X-rays show “ground-glass” bone appearance and cortical thinning in FD lesions.
• Bone scans reveal areas of high uptake corresponding to active lesions.

Management Strategies

Treating osteomalacia associated with McCune-Albright syndrome involves correcting phosphate and vitamin D deficits and addressing FD lesions:

1. Phosphate supplementation

   • Oral phosphate salts, divided doses throughout the day.
   • Monitor for gastrointestinal side effects (diarrhea, cramps).

2. Active vitamin D analogs

   • Calcitriol or alfacalcidol to bypass impaired 1α-hydroxylase.
   • Helps increase intestinal absorption of calcium and phosphate.

3. Monitoring

   • Regular blood tests for serum phosphate, calcium, creatinine and alkaline phosphatase.
   • Adjust doses to maintain phosphate in the low-normal range and avoid hypercalcemia.

4. Bisphosphonates (in selected cases)

   • Intravenous pamidronate or zoledronic acid may reduce bone pain and fracture risk.
   • Their effect on FGF23 levels is variable.

5. Orthopedic interventions

   • Surgical correction of severe deformities or fractures.
   • Weight-bearing restrictions until bone strength improves.

6. Experimental therapies

   • Anti-FGF23 antibodies (e.g., burosumab) are under investigation for genetic hypophosphatemias but may have future roles in FD/MAS.

Living with FD/MAS and Osteomalacia

• Regular follow-up with an endocrinologist and orthopedic specialist is essential.
• Physical therapy can improve muscle strength and gait.
• Pain management may include acetaminophen or non-steroidal anti-inflammatory drugs.
• Be alert for signs of complications: severe pain, new fractures, or symptoms of endocrine excess.

If you’re experiencing persistent bone pain, muscle weakness or unexplained fatigue, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s a quick way to gather information before talking to your healthcare provider.

Key Takeaways

• GNAS mutations in FD/MAS cause overactive cAMP signaling in bone cells.
• Mutant osteoblasts and osteocytes produce excess FGF23, leading to phosphate wasting and low calcitriol.
• Chronic phosphate depletion and vitamin D deficiency result in osteomalacia associated with McCune-Albright syndrome.
• Management focuses on phosphate and active vitamin D supplementation, symptom monitoring and, in some cases, bisphosphonates or surgery.
• Ongoing follow-up with specialists helps optimize bone health and quality of life.

This overview is based on current research in endocrinology and bone biology. If you have any serious or persistent symptoms, speak to a doctor promptly to rule out life-threatening complications and to discuss personalized treatment options.